NCT05761028View on ClinicalTrials.gov

A Study of CM310 in Subjects With Moderate to Severe Asthma

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

May 31, 2032

Study Completion Date

May 31, 2032

Conditions
Moderate to Severe Asthma
Interventions
DRUG

CM310

CM310 Recombinant Humanized Monoclonal Antibody Injection

OTHER

Placebo

Placebo

Trial Locations (1)

100000

RECRUITING

China-Japan Friendship Hospital, Beijing

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY